Oxidative stress and immunoglobulin levels in patients with hodgkin's lymphoma

Abstract EN

Objective : To assess, oxidative stress (by measuring malondialdehyde "MDA" which reflects lipid peroxidation, and total antioxidant status "TAS" ), and immunoglobulin levels (IgA, IgG, IgM) in patients with Hodgkin's lymphoma before and one month after starting cytotoxic drugs, in comparison with controls. Design : case-control study Setting : this study was conducted in the Hospital of Nuclear Medicine and Department of Pharmacology, college of Medicine, University of Mosul. Patients and Methods :twenty-three patients with Hodgkin’s lymphoma were included in this study together with 24 apparently healthy subjects taken as a control.

Initially for both patients and control, serum MDA, TAS and immunoglobulin levels (IgA, IgG, IgM) were measured and reported one month from starting specific cytotoxic drugs for the patient groups and after one month gap period for the control using especial commercial kits from Randox company (UK), for measuring TAS and immunoglobulin levels, while measurement of MDA was done by laboratory method. Results : before starting cytotoxic regimen, there was a highly significant rise in serum MDA concentration in patients with Hodgkin's lymphoma in comparison with control.

After one month from there was a highly significant rise in serum MDA concentration and a significant reduction in TAS and serum immunoglobulin levels.

By comparing the period before and after starting cytotoxic regimen in patients with lymphoma, there was a significant rise in MDA and a significant reduction in TAS and immunoglobulin levels with the exception of IgM which showed insignificant reduction Conclusion : This study revealed a rise in the oxidative stress; to which patients with Hodgkin's lymphoma were liable to, by the effect of specific cytotoxic regimen.

This is reflected by the rise in the serum level of MDA and a reduction in the TAS after cytotoxic regimen.

It also indicated a reduction in immunity of such patients during cytotoxic regimen as reflected by a reduction in immunoglobulin levels.